Seizure Management in Brain Tumor Patients

Introduction to Seizure Management

The European Association of Neuro-Oncology (EANO) and European Society for Medical Oncology (ESMO) guidelines recommend avoiding phenytoin entirely in patients with brain metastases requiring seizure control, and using lamotrigine or levetiracetam instead, due to significant drug interactions with steroids and chemotherapy agents commonly used in cancer treatment 1, 2, 3

Enzyme-inducing anticonvulsants like phenytoin are explicitly contraindicated in brain tumor patients according to EANO-ESMO guidelines (Level III, Grade D recommendation) 2, 3
Phenytoin has significant interactions with corticosteroids (dexamethasone), which are frequently used to manage cerebral edema in metastatic brain disease 1, 2

Lamotrigine is explicitly recommended as a first-line option by EANO-ESMO guidelines alongside levetiracetam for brain tumor-related seizures 2, 3, 4
The EANO-ESMO guidelines recommend lamotrigine due to its lack of enzyme-inducing properties, which avoids drug interactions with chemotherapy and steroids 4, 5

If starting anticonvulsant therapy de novo, initiate levetiracetam 1,000-3,000 mg/day as first-line for immediate effect, and consider lamotrigine as alternative if levetiracetam causes psychiatric side effects (mood changes, behavioral disturbances occur in some patients) 1, 4, 5
Never use phenytoin, carbamazepine, or phenobarbital as first-choice agents in this population 1, 2, 3

Continue anticonvulsants until local tumor control is achieved through surgery, radiation, or radiosurgery, then consider tapering within weeks if near-gross total resection was accomplished 4, 5
Question patients about seizure occurrences at every follow-up visit, and obtain serum drug levels if seizures are not controlled or to assess compliance 4, 5
Obtain repeat MRI if seizures worsen, as this often indicates tumor progression rather than medication failure 4, 5